WO1998056773A1 - Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic - Google Patents

Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic Download PDF

Info

Publication number
WO1998056773A1
WO1998056773A1 PCT/EP1998/003428 EP9803428W WO9856773A1 WO 1998056773 A1 WO1998056773 A1 WO 1998056773A1 EP 9803428 W EP9803428 W EP 9803428W WO 9856773 A1 WO9856773 A1 WO 9856773A1
Authority
WO
WIPO (PCT)
Prior art keywords
weak
modification
medium
strong
triazole
Prior art date
Application number
PCT/EP1998/003428
Other languages
French (fr)
Inventor
Robert Portmann
Urs Christoph Hofmeier
Andreas Burkhard
Walter Scherrer
Martin Szelagiewicz
Original Assignee
Novartis Ag
Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998056773(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002256015A priority Critical patent/CA2256015C/en
Priority to AU84372/98A priority patent/AU725517B2/en
Priority to HU0002113A priority patent/HU225153B1/en
Priority to AT98934930T priority patent/ATE237599T1/en
Priority to PL330798A priority patent/PL192114B1/en
Priority to IL12573298A priority patent/IL125732A/en
Priority to JP53628998A priority patent/JP3672575B2/en
Priority to SI9830450T priority patent/SI0994864T1/en
Priority to NZ331370A priority patent/NZ331370A/en
Priority to SK1094-98A priority patent/SK283734B6/en
Priority to DE69813560T priority patent/DE69813560T2/en
Priority to BR9804946A priority patent/BR9804946A/en
Priority to EP98934930A priority patent/EP0994864B1/en
Priority to DK98934930T priority patent/DK0994864T3/en
Application filed by Novartis Ag, Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. filed Critical Novartis Ag
Priority to NO19983666A priority patent/NO329314B1/en
Publication of WO1998056773A1 publication Critical patent/WO1998056773A1/en
Priority to HK00106807A priority patent/HK1028242A1/en
Priority to HK00107340A priority patent/HK1028031A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • Example 4 Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic.
  • the compound 1- (2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3- triazole-4-carboxylic acid, the procedure being analogous to Example 2.
  • EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to Example 4 is used in conjunction with Example 2, the crude 1 -(2,6- difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted. It has now surprisingly been found that the different crystal modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization. Description of the invention
  • 1-(2,6-Difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide can be obtained in the novel crystal modifications A, A', B and C. These crystal modifications differ with respect to their thermodynamic stability, in their physical parameters, such as the absorption pattern of IR and Raman spectra, in X-ray structure investigations and in their preparation processes.
  • the invention relates to the novel crystal modifications B and C, their preparation and use in pharmaceutical preparations comprising this crystal modification.
  • the modification A' compared with A, has defects in the crystal lattice. These are detectable, for example, by X-ray analysis, e.g. by smaller line spacings with otherwise predominantly identical lines or bands.
  • the crystal modification A of 1 -(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide melts at 242°C (239-245°C).
  • modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm '1 and 3092 cm “1 [cf. Figure 1], which are not present in the FT-IR spectra of the modifications B and C. In the range 4000-600 cm '1 , inter alia the following bands are obtained for modification A: 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781 , 723, 688 and 640 cm "1 .
  • the apparatus IFS 88 (Bruker) can be used for recording of each of the FT-IR spectra.
  • the modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the band at 1080 cm '1 [cf. Figure 2], which is not present in the Raman spectra of the modifications B and C. In the range 3400-300 cm '1 , inter alia the following bands are obtained for the modification A: 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061 , 1036, 1014, 840, 724, 691 , 667, 550, 499, 437 and 368 cm '1 .
  • the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
  • the modification A has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 10.5 A, 5.14 A, 4.84 A, 4.55 A, 4.34 A, 4.07 A, 3.51 A, 3.48 A, 3.25 A, 3.19 A, 3.15 A, 3.07 A, 2.81 A [cf. Table 1].
  • the patterns recorded on X-ray film were measured using an LS-18 line scanner from Johannsson, Taby (Sweden) and evaluated using the Scanpi software (P.E.Werner, University of Sweden).
  • Characteristic for the modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230°C to 260°C. The peak temperature is 239- 245°C, and the endothermic signal is 209 J/g +/- 10 J/g. The measurement was carried out on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute. The typical sample quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.
  • Crystals of the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattern in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 A and 3.64 A, 3.51 A and 3.48 A, 3.19 A and 3.15 A.
  • the novel modification B differs from the modification A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 1678 cm "1 [cf . Figure 1 ], which is not to be observed in the corresponding spectra of the modifications A and C.
  • the following bands are obtained for the modification B: 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051 , 1036, 1028, 889, 837, 800, 719, 667 and 645 cm "1 .
  • the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
  • the novel modification B differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm “1 and 1086 cm '1 [cf. Figure 2], which are not present in the Raman spectra of the modifications A and C.
  • the following bands are obtained for the modification B: 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441 , 1391 , 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm '1 .
  • the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
  • the novel modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A, 2.83 A [cf. Table U-
  • the novel modification B has, in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239- 245°C), a weak thermal signal at 205°C (180° - 220°C) as a typical distinguishing feature compared with the modifications A or A' and C.
  • the novel modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 3137 cm “1 [cf. Figure 1], which is not to be observed in the corresponding spectra of the modifications A and B. In the range 4000-600 cm " , inter alia the following bands are obtained for the novel modification C: 3396, 3287, 3137, 1657, 1631 , 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm "1 .
  • the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
  • the modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm '1 and 1602 cm “1 [cf. Figure 2], which are not present in the Raman spectra of the modifications A and B.
  • the following bands are obtained for the modification C: 3137, 3080, 3012, 2971 , 1673, 1629, 1602, 1561 , 1436, 1271 , 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm '1 .
  • the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
  • the novel modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A [cf . Table 1 ].
  • the modification C has, in addition to an endothermic signal in the range of 230°C to 260°C (peak temperature 239- 245°C), a very broad, weak, exothermic signal in the region of 180°C compared with the modifications A or A' and B.
  • Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.
  • modification B has a substantially faster dissolution rate in water and gastric fluid than modification A or A'. Consequently, when modification B is used therapeutically, a rapid onset of action is achieved, which is particularly advantageous, for example in an acute epilepsy attack.
  • the invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 1678 cm '1 .
  • the invention relates to the modification B of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A and 2.83 A, determined by means of an X-ray powder pattern.
  • the invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
  • the invention relates to the modification B of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205°C (180-220°C) in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239-245°C).
  • the invention furthermore relates to the crystal modification C of 1 -(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 3137 cm '1 .
  • the invention relates to the modification C of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A, determined by means of an X-ray powder pattern.
  • the invention relates to modification C of 1 -(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carbox- amide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
  • the invention relates to the modification C of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having in the thermogram in differential scanning calorimetry a very broad weak exothermic signal in the region of 180°C, in addition to an endothermic signal in the range from 230°C-260°C (peak temperature 239-245°C).
  • the invention relates to the essentially pure forms of the modifications B and C of 1-(2,6- difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide.
  • the term "essentially pure form” means purity of >95%, in particular >98%, primarily >99%, based on the modifications B and C.
  • the invention relates to pharmaceutical preparations comprising the modifications B and C of 1 -(2,6-dif luorobenzyl)-1 H-1 , 2, 3-triazole-4-carboxamide.
  • the invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof.
  • the invention relates to the use of the modifications B and C of 1 (2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.
  • novel modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for example oral, or parenteral administration.
  • novel modifications B and C of 1 -(2,6-dif iuorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions.
  • the pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers.
  • excipients for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers.
  • the present pharmaceutical preparations comprise from about 0.1% to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.
  • the invention also relates to the use of the modifications B and C of 1 -(2,6-difluorobenzyl)- 1 H-1 ,2,3-triazole-4-carboxamide as a drug, preferably in the form of pharmaceutical preparations.
  • the dosage may depend on various factors, such as method of administration, species, age and/or individual condition.
  • the doses to be administered daily are between about 0.25 and about 10 mg/kg in the case of oral administration, and preferably between about 20 mg and about 500 mg for warm-blooded species having a body weight of about 70 kg.
  • 1-(2,6-Difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide (15.0 g) is dissolved in acetic acid (120 ml) at about 90°C while stirring. The solution is cooled to 20°C in the course of about 8 minutes, a suspension forming. The product is immediately isolated by filtration, washed with toluene (120 ml) and dried in vacuo at about 60°C. 10.1 g of the product are obtained as modification C. Yield 67.3%.
  • Film-coated tablets each containing, for example, 100, 200 or 400 mg of the modification B or C of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide with the following composition per dosage unit:
  • Titanium dioxide 0.83 1.66 3.32
  • the active ingredient is granulated with demineralized water. Milled lactose, maize starch, Avicel PH 102, cellulose-HP-M-603 and sodium laurylsulfate are added to the above mixture and granulated with demineralized water.
  • the moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.
  • the tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.
  • Figure 1 shows the FT-IR spectra of the KBr pellets of crystal modifications A, B and C.
  • Figure 2 shows the FT-Raman spectra of the powder of modifications A, B and C.

Abstract

The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy and pharmaceutical preparations comprising these crystal modifications.

Description

CRYSTAL MODIFICATION OF l-(2,6-DIFLUOROBENZYL)-lH-l,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE
AS ANΉEPILEFΠC
Background of the invention
The compound 1 -(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide of the formula
Figure imgf000003_0001
is described in the European Patent Application with the Publication No. 0 199 262 A2 (EP 199262), for example in Example 4. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic. The compound 1- (2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3- triazole-4-carboxylic acid, the procedure being analogous to Example 2.
EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to Example 4 is used in conjunction with Example 2, the crude 1 -(2,6- difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted. It has now surprisingly been found that the different crystal modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization. Description of the invention
1-(2,6-Difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide can be obtained in the novel crystal modifications A, A', B and C. These crystal modifications differ with respect to their thermodynamic stability, in their physical parameters, such as the absorption pattern of IR and Raman spectra, in X-ray structure investigations and in their preparation processes.
The invention relates to the novel crystal modifications B and C, their preparation and use in pharmaceutical preparations comprising this crystal modification.
The modification A', compared with A, has defects in the crystal lattice. These are detectable, for example, by X-ray analysis, e.g. by smaller line spacings with otherwise predominantly identical lines or bands.
The crystal modification A of 1 -(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide melts at 242°C (239-245°C).
In the FT infrared (FT-IR) spectrum (KBr pellet - transmission method), modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm'1 and 3092 cm"1 [cf. Figure 1], which are not present in the FT-IR spectra of the modifications B and C. In the range 4000-600 cm'1, inter alia the following bands are obtained for modification A: 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781 , 723, 688 and 640 cm"1. For example, the apparatus IFS 88 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180°), the modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the band at 1080 cm'1 [cf. Figure 2], which is not present in the Raman spectra of the modifications B and C. In the range 3400-300 cm'1, inter alia the following bands are obtained for the modification A: 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061 , 1036, 1014, 840, 724, 691 , 667, 550, 499, 437 and 368 cm'1. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
The modification A has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 10.5 A, 5.14 A, 4.84 A, 4.55 A, 4.34 A, 4.07 A, 3.51 A, 3.48 A, 3.25 A, 3.19 A, 3.15 A, 3.07 A, 2.81 A [cf. Table 1]. The measurement can be carried out, for example, in transmission geometry on an FR 552 Guinier camera from Enraf-Nonius, Delft (The Netherlands), using copper Kocι radiation (wavelength λ = 1.54060 A). The patterns recorded on X-ray film were measured using an LS-18 line scanner from Johannsson, Taby (Sweden) and evaluated using the Scanpi software (P.E.Werner, University of Stockholm).
Characteristic for the modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230°C to 260°C. The peak temperature is 239- 245°C, and the endothermic signal is 209 J/g +/- 10 J/g. The measurement was carried out on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute. The typical sample quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.
Crystals of the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattern in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 A and 3.64 A, 3.51 A and 3.48 A, 3.19 A and 3.15 A.
In the FT-IR spectrum (KBr pellet - transmission method), the novel modification B differs from the modification A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 1678 cm"1 [cf . Figure 1 ], which is not to be observed in the corresponding spectra of the modifications A and C. In the range 4000-600 cm'1, inter alia the following bands are obtained for the modification B: 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051 , 1036, 1028, 889, 837, 800, 719, 667 and 645 cm"1. For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180°), the novel modification B differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm"1 and 1086 cm'1 [cf. Figure 2], which are not present in the Raman spectra of the modifications A and C. In the range 3400-300 cm"1, inter alia the following bands are obtained for the modification B: 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441 , 1391 , 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm'1. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
The novel modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A, 2.83 A [cf. Table U-
In the thermogram in differential scanning calorimetry, the novel modification B has, in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239- 245°C), a weak thermal signal at 205°C (180° - 220°C) as a typical distinguishing feature compared with the modifications A or A' and C.
In the FT-IR spectrum (KBr pellet - transmission method), the novel modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic is a band at 3137 cm"1 [cf. Figure 1], which is not to be observed in the corresponding spectra of the modifications A and B. In the range 4000-600 cm" , inter alia the following bands are obtained for the novel modification C: 3396, 3287, 3137, 1657, 1631 , 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm"1. For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180°), the modification C differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm'1 and 1602 cm"1 [cf. Figure 2], which are not present in the Raman spectra of the modifications A and B. In the range 3400-300 cm'1, inter alia the following bands are obtained for the modification C: 3137, 3080, 3012, 2971 , 1673, 1629, 1602, 1561 , 1436, 1271 , 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm'1. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT Raman spectra.
The novel modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A [cf . Table 1 ]. In the thermogram in differential scanning calorimetry, the modification C has, in addition to an endothermic signal in the range of 230°C to 260°C (peak temperature 239- 245°C), a very broad, weak, exothermic signal in the region of 180°C compared with the modifications A or A' and B.
Figure imgf000007_0001
Figure imgf000008_0001
Single crystal X-rav analysis:
Crystal quality and unit cell of modifications A, B, and C were verified by Weissenberg and precession photographs. The intensities were measured on a four-axis Nonius CAD-4 diffractometer. The structures were solved with the SHELXS-97 and refined with the SHELXL-97 software.
Modification A
Space group: Pna2i - orthorhombic
Cell dimensions: a = 24.756 (5)A b = 23.069 (4)A c = 5.386 (1 )A v = 3075.9 A3 Z = 12 Dx = 1.543 gem"3 v per formula: V2 = 256.3 A3
9011 unique reflections; 2479 thereof significant with I > 2σ (I). 557 parameters refined. Position of all H atoms found by difference Fourier maps and refined isotropically. Reliability index Ri: 3.65% (wR2 for all 9011 reflections: 11.34%).
Modification B
Space group: P '1 -triclinic
Cell dimensions: a = 5.326(1) A b = 11.976(2) A c = 17.355(3) A α = 107.22(3)° β = 92.17(3)° γ = 102.11 (3)° v = 1027.9 A3 Z = 4 Dx = 1.539 gem'3 v per formula Vz = 257.0 A3
4934 unique reflections; 834 thereof significant with I > 2σ (I). 232 parameters refined. Position of all H atoms found by difference Fourier maps and refined isotropically. Reliability index R,: 4.20% (wR2 for all 4934 reflections: 7.93%).
Modification C
Space group: P2JC - monoclinic
Cell dimensions: a = 10.982(2) A b = 5.350(1) A c = 17.945(3) A β = 91.59(1 )° v = 1053.9 A3 Z = 4 Dx = 1.501 gem'3 v per formula: V2 = 263.5 A3
3073 unique reflections; 1071 thereof significant with I > 2σ (I). 187 parameters refined. Position of all H atoms found by difference Fourier maps and refined isotropically. Reliability index R,: 5,02% (wR2 for all 3073 reflections: 14.55%).
Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.
The modifications B and C have significant advantages compared with the modification A or A'.
Thus, it was found, for example, that modification B has a substantially faster dissolution rate in water and gastric fluid than modification A or A'. Consequently, when modification B is used therapeutically, a rapid onset of action is achieved, which is particularly advantageous, for example in an acute epilepsy attack.
The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 1678 cm'1. The invention relates to the modification B of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A and 2.83 A, determined by means of an X-ray powder pattern.
The invention relates to the modification B of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
The invention relates to the modification B of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205°C (180-220°C) in addition to an endothermic signal in the range from 230°C to 260°C (peak temperature 239-245°C).
The invention furthermore relates to the crystal modification C of 1 -(2,6-difluorobenzyl)-1 H- 1 ,2,3-triazole-4-carboxamide, having the following absorption in the infrared spectrum (KBr pellet - transmission method): band at 3137 cm'1.
The invention relates to the modification C of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A, determined by means of an X-ray powder pattern.
The invention relates to modification C of 1 -(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carbox- amide, having the characteristic lines with interplanar spacings (d values) as shown in Table 1.
The invention relates to the modification C of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide, having in the thermogram in differential scanning calorimetry a very broad weak exothermic signal in the region of 180°C, in addition to an endothermic signal in the range from 230°C-260°C (peak temperature 239-245°C).
The invention relates to the essentially pure forms of the modifications B and C of 1-(2,6- difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide. The term "essentially pure form" means purity of >95%, in particular >98%, primarily >99%, based on the modifications B and C.
The invention relates to pharmaceutical preparations comprising the modifications B and C of 1 -(2,6-dif luorobenzyl)-1 H-1 , 2, 3-triazole-4-carboxamide. The invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof. The invention relates to the use of the modifications B and C of 1 (2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.
The novel modifications B and C of 1-(2,6-difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for example oral, or parenteral administration. Furthermore, the novel modifications B and C of 1 -(2,6-dif iuorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions. The pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations comprise from about 0.1% to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.
The invention also relates to the use of the modifications B and C of 1 -(2,6-difluorobenzyl)- 1 H-1 ,2,3-triazole-4-carboxamide as a drug, preferably in the form of pharmaceutical preparations. The dosage may depend on various factors, such as method of administration, species, age and/or individual condition. The doses to be administered daily are between about 0.25 and about 10 mg/kg in the case of oral administration, and preferably between about 20 mg and about 500 mg for warm-blooded species having a body weight of about 70 kg.
The preparation of the modifications B and C is carried out, for example, as described in the embodiments below.
Example 1 : Modification B
1-(2,6-Difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide (18.29 kg) is dissolved in formic acid (89.3 kg) at 58-63°C while stirring. The solution is discharged in the course of about 30 minutes onto stirred methanol (105.5 I) at 20°C to 0°C, after which washing with formic acid (6.1 kg) is carried out. A suspension forms. The product is isolated immediately by filtration and washed with cold methanol (150 I, about 4°C). By drying in vacuo at about 60°C, the product is obtained as modification B in a yield of about 94%.
Example 2: Modification C
1-(2,6-Difluorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide (15.0 g) is dissolved in acetic acid (120 ml) at about 90°C while stirring. The solution is cooled to 20°C in the course of about 8 minutes, a suspension forming. The product is immediately isolated by filtration, washed with toluene (120 ml) and dried in vacuo at about 60°C. 10.1 g of the product are obtained as modification C. Yield 67.3%.
Formulation Example 1 :
Film-coated tablets each containing, for example, 100, 200 or 400 mg of the modification B or C of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide with the following composition per dosage unit:
Core material mg mg mg
Active ingredient 100.00 200.00 400.00
Anhydrous, colloidal silica 0.88 1.75 3.5
Microcrystalline cellulose 36.62 73.25 146.50
Hydroxypropylmethyl- 5.00 10.00 20.00 cellulose
Lactose 20.00 40.00 80.00
Magnesium stearate 2.00 4.00 8.00
Maize starch 10.00 20.00 40.00
Sodium carboxymethyl- 5.00 10.00 20.00 cellulose
Sodium laurylsulfate 0.50 1.00 2.00
Film coat mg mg mg
Hydroxypropylmethyl- 3.22 6.43 12.87 cellulose
Red iron oxide 0.04 0.09 0.18
Polyethylene glycol 8000, 0.58 1.16 2.32 flakes
Talc 2.33 4.66 9.31
Titanium dioxide 0.83 1.66 3.32
The active ingredient is granulated with demineralized water. Milled lactose, maize starch, Avicel PH 102, cellulose-HP-M-603 and sodium laurylsulfate are added to the above mixture and granulated with demineralized water.
The moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.
The tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.
Description of the Figures
Figure 1 shows the FT-IR spectra of the KBr pellets of crystal modifications A, B and C.
Figure 2 shows the FT-Raman spectra of the powder of modifications A, B and C.
In both Figures, the modification A is denoted by the symbol *, the modification B by the symbol ** and the modification C by the symbol ***.

Claims

WHAT IS CLAIMED IS:
1. A modification B of the compound 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide of the formula
Figure imgf000016_0001
having characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A and 2.83 A, determined by means of an X-ray powder pattern.
2. A modification according to claim 1 , which has an X-ray powder pattern having the following characteristic lines with inteφlanar spacings (d values) of 11.0 A (medium), 8.3 A (medium), 8.1 A (very weak), 5.68 A (very weak), 5.18 A (very strong), 5.11 A (weak), 4.88 A (medium), 4.80 A (strong), 4.71 A (very weak), 4.61 A (weak), 4.45 A (weak), 4.42 A (strong), 4.33 A (very strong), 4.19 A (medium), 4.12 A (strong), 4.09 A (weak), 3.99 A (very weak), 3.95 A (very weak), 3.84 A (weak), 3.81 A (medium), 3.65 A (weak), 3.61 A (very weak), 3.58 A (very weak), 3.54 A (weak), 3.50 A (medium), 3.47 A (very weak), 3.41 A (medium), 3.36 A (very strong), 3.32 A (strong), 3.28 A (medium), 3.24 A (medium), 3.10 A (weak), 3.07 A (weak), 3.05 A (medium), 2.93 A (weak), 2.88 A (weak), 2.87 A (very weak) 2.83 A (medium), 2.66 A (weak), 2.63 A (very weak), 2.55 A (weak), 2.50 A (weak), 2.46 A (weak), 2.44 A (weak), 2.37 A (weak), 2.35 A (weak).
3. A modification according to claim 1 or 2, having the following absorption in the FT-IR spectrum (KBr pellet - transmission method): 1678 cm"1.
4. A modification according to claim 3, having the following absoφtions in the FT-IR spectrum (KBr pellet - transmission method): 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051 , 1036, 1028, 889, 837, 800, 719, 667 and 645 cm'1.
5. A modification according to any one of claims 1-4, having the following absorptions in the FT-Raman spectrum (powder - reflection method 180┬░): 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441 , 1391 , 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm'1.
6. A modification B according to any one of claims 1 -5, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205┬░C (180-220┬░C) in addition to an endothermic signal in the range from 230┬░C to 260┬░C (peak temperature 239-245┬░C).
7. A modification C of the compound 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide of the formula
Figure imgf000017_0001
having characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A, determined by means of an X-ray powder pattern.
8. A modification according to claim 7, having an X-ray powder pattern with the following characteristic lines with inteφlanar spacings (d values) of 9.0 A (medium), 7.0 A (weak), 5.49 A (weak), 5.11 A (very weak), 4.80 A (weak), 4.73 A (strong), 4.65 A (very strong), 4.47 A (very weak), 4.19 A (very weak), 4.11 A (very weak), 3.98 A (very weak), 3.83 A (very weak), 3.75 A (strong), 3.73 A (weak), 3.54 A (medium), 3.50 A (weak), 3.42 A (strong), 3.25 A (medium), 2.88 A (very weak), 2.80 A (very weak), 2.74 A (very weak), 2.67 A (very weak), 2.64 A (weak).
9. A modification according to claim 7 or 8, having the following absoφtion in the infrared spectrum (KBr pellet - transmission method): 3137 cm'1.
10. A modification according to claim 9, having the following absoφtions in the infrared spectrum (KBr pellet - transmission method): 3396, 3287, 3137, 1657, 1631 , 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm"1.
11. A modification according to any one of claims 7-10, having the following absoφtions in the FT-Raman spectrum (powder - reflection method 180°): 3137, 3080, 3012, 2971 , 1673, 1629, 1602, 1561 , 1436, 1271 , 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm'1.
12. A modification C according to any one of claims 7-11 , having in the thermogram in differential scanning calorimetry a very broad, weak, exothermic signal in the region of
180┬░C, in addition to an endothermic signal in the range from 230┬░C to 260┬░C (peak temperature 239-245┬░C).
13. A modification B or C according to any one of claims 1-12 in essentially pure form.
14. A pharmaceutical preparation comprising the modification B or C of the compound 1- (2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4-carboxamide according to any one of claims 1 -13 and pharmaceutically usable excipients and additives.
15. The use of the modification B or C of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide according to any one of claims 1-13 as a pharmaceutical preparation.
16. The use of the modification B or C of 1 -(2,6-dif luorobenzyl)-1 H-1 ,2,3-triazole-4- carboxamide according to any one of claims 1-13 for the preparation of a pharmaceutical preparation for the treatment of epilepsy and subindications thereof.
PCT/EP1998/003428 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic WO1998056773A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AU84372/98A AU725517B2 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3- triazole-4-carboxamide and its use as antiepileptic
SK1094-98A SK283734B6 (en) 1997-06-10 1998-06-08 Crystal modification of compound 1-(2,6-difluorobenzyl)-1H-1,2,3- triazole-4-carboxamide, pharmaceutical compositions containing them and use thereof
NZ331370A NZ331370A (en) 1997-06-10 1998-06-08 Crystal modification B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof
AT98934930T ATE237599T1 (en) 1997-06-10 1998-06-08 CRYSTAL MODIFICATION OF 1-(2,6-DIFLUORBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBON AUREAMIDE AND ITS USE AS AN ANTI-EPILEPTIC
PL330798A PL192114B1 (en) 1997-06-10 1998-06-08 Crystalline form of a pharmaceutic agent
IL12573298A IL125732A (en) 1997-06-10 1998-06-08 Crystal modification of the compound 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and a pharmaceutical composition for treating epilepsy comprising the same
JP53628998A JP3672575B2 (en) 1997-06-10 1998-06-08 Drug crystal deformation
SI9830450T SI0994864T1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
HU0002113A HU225153B1 (en) 1997-06-10 1998-06-08 Crystal modifications of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide, their use and pharmaceutical compositions containing them
CA002256015A CA2256015C (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
BR9804946A BR9804946A (en) 1997-06-10 1998-06-08 Crystal modification of a pharmaceutical agent
DE69813560T DE69813560T2 (en) 1997-06-10 1998-06-08 CRYSTAL MODIFICATION OF 1- (2,6-DIFLUORBENZYL) -1H-1,2,3-TRIAZOL-4-CARBONIC ACID AMIDE AND ITS USE AS AN ANTI-PILEPTIC
EP98934930A EP0994864B1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
DK98934930T DK0994864T3 (en) 1997-06-10 1998-06-08 Crystal modification of 1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide and its use as an antiepileptic
NO19983666A NO329314B1 (en) 1997-06-10 1998-08-11 Crystal modification of a pharmaceutical agent, its use, and pharmaceutical composition containing the crystal modification.
HK00106807A HK1028242A1 (en) 1997-06-10 2000-10-25 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3,-triazole-4-carboxamide and its use as antiepileptic
HK00107340A HK1028031A1 (en) 1997-06-10 2000-11-17 Crystal modification of 1-(2,6-difluorobenzyl)-IH-1,2,3-triazole-4-carboxamide and its use as antiepileptic.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1404/97 1997-06-10
CH140497 1997-06-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12533098A A-371-Of-International 1997-06-10 1998-09-08
US59968800A Continuation 1997-06-10 2000-06-22

Publications (1)

Publication Number Publication Date
WO1998056773A1 true WO1998056773A1 (en) 1998-12-17

Family

ID=4209650

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1998/003427 WO1998056772A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic
PCT/EP1998/003428 WO1998056773A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003427 WO1998056772A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Country Status (37)

Country Link
US (6) US6740669B1 (en)
EP (2) EP0994864B1 (en)
JP (2) JP3672575B2 (en)
KR (2) KR100425656B1 (en)
CN (3) CN1298708C (en)
AR (4) AR012946A1 (en)
AT (2) ATE232852T1 (en)
AU (2) AU725517B2 (en)
BR (2) BR9804947A (en)
CA (3) CA2256013C (en)
CO (2) CO4940452A1 (en)
CY (1) CY2007014I1 (en)
CZ (2) CZ292260B6 (en)
DE (3) DE69811500T2 (en)
DK (2) DK0994863T3 (en)
ES (2) ES2197485T3 (en)
FR (1) FR07C0037I2 (en)
HK (3) HK1028242A1 (en)
HU (2) HU226107B1 (en)
ID (2) ID27660A (en)
IL (2) IL125732A (en)
LU (1) LU91345I2 (en)
MY (2) MY120156A (en)
NL (1) NL300284I2 (en)
NO (2) NO329314B1 (en)
NZ (2) NZ331370A (en)
PE (2) PE80999A1 (en)
PL (2) PL191943B1 (en)
PT (1) PT994864E (en)
RU (2) RU2198167C2 (en)
SI (2) SI0994863T1 (en)
SK (2) SK283685B6 (en)
TR (2) TR199801630T1 (en)
TW (2) TW526195B (en)
UY (1) UY25844A1 (en)
WO (2) WO1998056772A1 (en)
ZA (2) ZA984967B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750028B2 (en) 1997-06-10 2010-07-06 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
ITMI20110718A1 (en) * 2011-04-29 2012-10-30 Dipharma Francis Srl PROCEDURE FOR PURIFICATION OF RUFINAMIDE
US8884026B2 (en) 2010-04-30 2014-11-11 Laboratorios Lesvi, S.L. Process for preparing rufinamide intermediate

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040233A1 (en) * 2002-05-31 2005-03-23 Schering Corp XANTINA FOSFODIESTERASA V INHIBITING POLYMORPHES
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
NZ591725A (en) 2008-10-13 2012-09-28 Cipla Ltd PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
CN101768124B (en) * 2008-12-30 2012-01-04 北京本草天源药物研究院 Medicine crystal, preparation method and purpose thereof
IT1395736B1 (en) * 2009-08-04 2012-10-19 Dipharma Francis Srl CRYSTALLINE FORMS OF RUFINAMIDE
EP2473051B1 (en) * 2009-09-04 2016-02-10 Tactical Therapeutics, Inc. Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199262A2 (en) * 1985-04-18 1986-10-29 Ciba-Geigy Ag Fluorinated benzyl triazole compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A (en) 1982-12-23 1984-06-24 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (en) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd Method for depositing crystal of compound having plural crystal forms
WO1991001724A1 (en) 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
CA2095444C (en) 1990-11-06 2001-06-19 Shuichi Sakamoto Fused pyrazine derivatives
JP2753911B2 (en) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Crystal polymorph of N-tert-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride and method for producing the same
DE4217952A1 (en) 1992-05-30 1993-12-02 Basf Ag Quinoxaline-2,3 (1H, 4H) diones
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
WO1996026197A1 (en) 1995-02-22 1996-08-29 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
PT918758E (en) * 1996-07-11 2002-09-30 Novartis Ag PROCESS FOR THE PREPARATION OF 1-SUBSTITUTED 4-CYANO-1,2,3-TRIAZOLES
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199262A2 (en) * 1985-04-18 1986-10-29 Ciba-Geigy Ag Fluorinated benzyl triazole compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MÜNZEL K: "Der Einfluss der Formgebung auf die Wirkung eines Arzneimittels", FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG - PROGRESS IN DRUG RESEARCH - PROGRÈS DES RECHERCHES PHARMACEUTIQUES, vol. 10, 1966, Basel, CH, pages 227 - 30, XP002078506 *
MÜNZEL K: "Galenische Formgebung und Arzneimittelwirkung / Neue Erkenntnisse und Feststellungen", PROGRESS IN DRUG RESEARCH - FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG - PROGRÈS DES RECHERCHES PHARMACEUTIQUES, vol. 14, 1970, Basel, CH, pages 309 - 21, XP002078507 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750028B2 (en) 1997-06-10 2010-07-06 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
US8076362B2 (en) 1997-06-10 2011-12-13 Novartis Ag Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
US8884026B2 (en) 2010-04-30 2014-11-11 Laboratorios Lesvi, S.L. Process for preparing rufinamide intermediate
ITMI20110718A1 (en) * 2011-04-29 2012-10-30 Dipharma Francis Srl PROCEDURE FOR PURIFICATION OF RUFINAMIDE
EP2518057A1 (en) * 2011-04-29 2012-10-31 Dipharma Francis S.r.l. Process for the purification of rufinamide
US8461190B2 (en) 2011-04-29 2013-06-11 Dipharma Francis S.R.L. Process for the purification of rufinamide

Also Published As

Publication number Publication date
HK1028031A1 (en) 2001-02-02
SK283685B6 (en) 2003-12-02
AU725528B2 (en) 2000-10-12
AU725517B2 (en) 2000-10-12
SI0994864T1 (en) 2003-10-31
EP0994864A1 (en) 2000-04-26
WO1998056772A1 (en) 1998-12-17
CN1298708C (en) 2007-02-07
KR100425656B1 (en) 2004-05-17
NO329315B1 (en) 2010-09-27
US20030125568A1 (en) 2003-07-03
EP0994864B1 (en) 2003-04-16
IL125732A (en) 2002-12-01
CN1259127A (en) 2000-07-05
CZ292481B6 (en) 2003-09-17
HK1028242A1 (en) 2001-02-09
TW526195B (en) 2003-04-01
US7750028B2 (en) 2010-07-06
CA2256013C (en) 2007-10-16
NO983666L (en) 1998-12-17
CZ292260B6 (en) 2003-08-13
KR100409168B1 (en) 2004-01-31
RU2194041C2 (en) 2002-12-10
DE122007000051I1 (en) 2007-11-08
AU8437298A (en) 1998-12-30
ZA984966B (en) 1999-01-11
CA2256013A1 (en) 1998-12-17
NO329314B1 (en) 2010-09-27
CY2007014I2 (en) 2009-11-04
JP2000516259A (en) 2000-12-05
RU2198167C2 (en) 2003-02-10
DE69813560T2 (en) 2004-02-05
AR061004A2 (en) 2008-07-30
US20060116520A1 (en) 2006-06-01
PL192114B1 (en) 2006-08-31
JP2000516258A (en) 2000-12-05
AR061005A2 (en) 2008-07-30
DE69811500D1 (en) 2003-03-27
BR9804946A (en) 1999-08-24
EP0994863B1 (en) 2003-02-19
US6455556B2 (en) 2002-09-24
CN1572789A (en) 2005-02-02
CA2256015C (en) 2008-06-03
SK109498A3 (en) 1998-12-02
US20040167186A1 (en) 2004-08-26
ZA984967B (en) 1999-01-11
HUP0002113A3 (en) 2002-09-30
BR9804947A (en) 1999-08-24
KR19990087835A (en) 1999-12-27
KR19990087836A (en) 1999-12-27
CZ253498A3 (en) 1999-04-14
NL300284I2 (en) 2007-11-01
ATE232852T1 (en) 2003-03-15
DE69811500T2 (en) 2004-04-01
ID21014A (en) 1999-04-08
SI0994863T1 (en) 2003-08-31
UY25844A1 (en) 2001-08-27
IL125733A (en) 2002-12-01
HK1028241A1 (en) 2001-02-09
HUP0002113A2 (en) 2001-02-28
JP3672574B2 (en) 2005-07-20
DK0994863T3 (en) 2003-05-26
JP3672575B2 (en) 2005-07-20
US20010037029A1 (en) 2001-11-01
SK109398A3 (en) 1998-12-02
PL191943B1 (en) 2006-07-31
MY120156A (en) 2005-09-30
ES2192779T3 (en) 2003-10-16
IL125732A0 (en) 1999-04-11
IL125733A0 (en) 1999-04-11
CA2256015A1 (en) 1998-12-17
US6740669B1 (en) 2004-05-25
AR012945A1 (en) 2000-11-22
HU226107B1 (en) 2008-04-28
AU8437198A (en) 1998-12-30
CY2007014I1 (en) 2009-11-04
ES2197485T3 (en) 2004-01-01
AR012946A1 (en) 2000-11-22
TW403740B (en) 2000-09-01
EP0994863A1 (en) 2000-04-26
NO983666D0 (en) 1998-08-11
CN1159300C (en) 2004-07-28
PE80999A1 (en) 1999-09-06
LU91345I9 (en) 2018-12-31
HUP0000798A3 (en) 2000-10-30
TR199801630T1 (en) 1999-06-21
PE79799A1 (en) 1999-09-03
PL330764A1 (en) 1999-05-24
MY125854A (en) 2006-08-30
US20100310655A1 (en) 2010-12-09
PL330798A1 (en) 1999-06-07
DE122007000051I2 (en) 2009-02-19
CZ253398A3 (en) 1999-04-14
FR07C0037I2 (en) 2008-05-16
NO983667L (en) 1998-12-17
ATE237599T1 (en) 2003-05-15
NZ331371A (en) 2000-08-25
TR199801631T1 (en) 1999-06-21
HU225153B1 (en) 2006-07-28
DK0994864T3 (en) 2003-07-21
HUP0000798A2 (en) 2000-10-30
NZ331370A (en) 2000-08-25
CO4940452A1 (en) 2000-07-24
NL300284I1 (en) 2007-10-01
NO983667D0 (en) 1998-08-11
US8076362B2 (en) 2011-12-13
CN1132820C (en) 2003-12-31
SK283734B6 (en) 2003-12-02
DE69813560D1 (en) 2003-05-22
CN1217716A (en) 1999-05-26
CA2614926A1 (en) 1998-12-17
ID27660A (en) 2001-04-19
FR07C0037I1 (en) 2007-08-17
PT994864E (en) 2003-07-31
CA2614926C (en) 2010-02-09
CO4940448A1 (en) 2000-07-24
LU91345I2 (en) 2007-09-04

Similar Documents

Publication Publication Date Title
US20060116520A1 (en) Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
MXPA98006950A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
MXPA98006951A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 125732

Country of ref document: IL

Ref document number: 98805675.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1998934930

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1998-2534

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 84372/98

Country of ref document: AU

Ref document number: 109498

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2256015

Country of ref document: CA

Ref document number: 2256015

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 331370

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1199800712

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1998/01631

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/006950

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1998 536289

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09125330

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1019980708150

Country of ref document: KR

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: PV1998-2534

Country of ref document: CZ

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1019980708150

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998934930

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 84372/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998934930

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1998-2534

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1019980708150

Country of ref document: KR